Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: Nationwide cohort study
Arthritis Rheumatol 2024 doi: 10.1002/art.42862 Epub ahead of print
Crude gastrointestinal perforation (GIP)incidence rate was higher for the JAKi group compared with those receiving adalimumab, however rates of GIP did not differ between JAKi and adalimumab groups in the weighted and adjusted model. Hoisnard et al compared the risk of GIP in patients initiating treatment with JAKis or adalimumab among real-world patients with rheumatic disease.
Patients initiating JAKi treatment were older, more likely to have RA, and more often had received other biologic therapy ≤2 years before the treatment index date. Weighted results were consistent regardless of the JAKi or rheumatic disease subgroup.
Keywords:
